Market Currents
More on Vertex Pharmaceutical (VRTX): Q3 results miss on all counts as the drug maker posted...
-
Thursday, November 1, 2012, 8:06 PM ETMore on Vertex Pharmaceutical (VRTX): Q3 results miss on all counts as the drug maker posted higher expenses and lower revenues, largely due to a drop in sales of Incivek, plus a decline in royalty income and an overall drop in collaborative revenue. Shares -3% AH.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
